Are you a public company looking for exposure? Contact RealPennies.com - 1.800.940.6559For more info: http://htre.realpennies.com H3 ENTERPRISES INCORPORATED (OTC: HTRE) up 48.11% on ThursdayH3 Enterprises Inc. has developed a powerful niche in three of the largest, fastest growing, and most profitable segments in the Entertainment Industry worldwide: Hip Hop Music, Video Gaming, and High Definition Flat Screen TV. These multi-faceted sectors have all been vertically integrated into an award winning franchise that has the opportunity to become the new home of the "Hip Hop Generation", the most sought after demographic in the world today. In a short period of time, H3 continues to put together the pieces necessary to fully capitalize on the seemingly insatiable appetite for all three of these market monsters through a series of strategic alliances and acquisitions, major celebrity signings, and the construction of a management team second to none. HTRE News: May 1 - H3 Set to Announce Major Company Developments H3 Enterprises, Inc. (OTC: HTRE) President and CEO, Dr. Benjamin Chavis, announced that he has scheduled a national teleconference and live video webcast for Monday, May 5, 2008 at 11:30am EDT. Dr. Chavis will discuss unfolding new developments that will likely have a dynamic impact on the future of H3. To join in the national teleconference dial 1-218-339-7800 and the participant access code is 178920. For more info: http://zoro.realpennies.comZORO MINING CORPORATION (OTCBB: ZORO) up 43.08% on ThursdayZoro Mining Corp. engages in the acquisition, exploration, and development of mineral properties in North America, South America, and Mexico. It has an option to acquire a 100% interest in six mineral property covering approximately 39,787 gross acres located in Chile, Peru, and Mexico with a focus on gold and copper prospects. The company was founded in 2004 under the name Rochdale Mining Corp. and changed its name to Zoro Mining Corp. in March 2007. Zoro Mining Corp. is based in Tucson, Arizona. ZORO News: May 1 - Zoro Mining Has Contracted for 8,000 Meters of Diamond Drilling at Its Don Beno Project, Region III Chile Zoro Mining Corp. (OTCBB: ZORO) announced that it is ready to commence up to an 8,000 meter (26,000 feet) diamond drilling program at its 100% owned Don Beno gold-copper project located 100 km from Copiapo in Region III, Chile. This drill program has been designed to drill targets from a recently completed geophysical I.P. survey. The geophysical mapping program at Don Beno, conducted by HydroGeophysics of Tucson, Arizona, included both electrical resistivity and induced polarization (IP) methods along linear transects of up to 8 km in length. Several large sulfidic IP targets were identified through approximately 33 line-kilometers among 5 transects. The targets are open ended to depth. The largest of the IP anomalies identified is roughly 4km by 2km in size, where the depth from surface to the sulfide mineralization is expected to be as little as 60 meters. These anomalies appear to be part of a system associated with targets which are presently defined or being drilled, on concessions directly adjoining Don Beno, currently being pursued by both SAMEX Mining Corp. and IPBX Resources. The Don Beno diamond drilling program will focus on the largest identified IP anomaly. Zoro has contracted for diamond drilling with PerfoAndes, a Chilean drilling company, which anticipates rig site mobilization and startup at the beginning of May, 2008. The holes will vary in depth but are envisioned to average approximately 500 meters. Zoro's main holdings are in the Don Beno, Escondida, Costa Rica and Rio Sur Districts in Chile, and the Yura District in Peru. For more info: http://hdvy.realpennies.comHEALTH DISCOVERY CORPORATION (OTCBB: HDVY) up 32.00% on Thursday Health Discovery Corporation operates as a pattern recognition company that uses mathematical techniques to analyze large amounts of data to uncover patterns. It licenses its support vector machines and fractal genomic modeling technologies to diagnostic and pharmaceutical companies. The company's discoveries include a subset of genes that separates BPH from prostate cancer and BPH from normal tissue patterns; a genetic biomarker signature, which identifies clinically high grade prostate cancer based on analysis of tissue samples; a set of leukemia genes that separates ALL-T-cell leukemia from ALL-B-cell leukemia; colon cancer-specific biomarkers, which is used in the development of diagnostic assays for cancer detection, disease discrimination, and potential vaccine; and an AIDS expression signature that separates AIDS brain cells from non-AIDS brain cells. It is also developing two breast cancer diagnostic technologies, including MammoSIGHT for detecting malignancy in mammograms; and MetastaSIGHT for identifying circulating tumor cells in the blood. The company was founded in 2001. It was formerly known as Direct Wireless Communications, Inc. and changed its name to Health Discovery Corporation in 2003. Health Discovery is based in Savannah, Georgia. HDVY News: April 30 - Health Discovery Corporation Announces Successful Clinical Trial Results for New Molecular Diagnostic Test for Prostate Cancer New Prostate Cancer Test Demonstrates Very High Accuracy Rate for Detecting Prostate Cancer Health Discovery Corporation (OTCBB: HDVY) ("HDC") announced the successful clinical trial results for HDC's new molecular diagnostic test for prostate cancer licensed exclusively to Clarient (NASD: CLRT), in which HDC will receive a 30 percent royalty based on reimbursements received by Clarient from third parties. The initial clinical validation study recently completed at Clarient from prostate tissues obtained in collaboration with MD Anderson Cancer Center demonstrated a very high success rate for identifying the presence of Grade 3 or higher prostate cancer cells (clinically significant cancer) in prostate cancer tissue. The new molecular diagnostic test achieved a Sensitivity of 100% meaning that the test correctly identified genomic evidence of prostate cancer cells in every tissue specimen known to be positive for prostate cancer. The test also demonstrated a very high success rate for correctly identifying those prostate specimens that did not have prostate cancer as being negative for prostate cancer and achieved a Specificity of 80% for identifying the non-cancer tissues, which included normal and benign prostatic hypertrophy (BPH) tissue, as not having genomic evidence of cancer. In the United States alone there are over 1 million prostate cancer tissue biopsy procedures performed annually. Approximately 25% of these tissue biopsies are reported "positive" indicating the presence of prostate cancer. The other 75% of prostate cancer tissue biopsies are reported as "negative" for the presence of cancer. However, one-third of the men with prostate cancer tissue biopsies that are reported as "negative" for prostate cancer (roughly 25%) actually do have prostate cancer that was missed by the first biopsy (False Negative). These men actually have prostate cancer that was missed by the initial tissue biopsy for a variety of reasons. Health Discovery Corporation's prostate cancer molecular diagnostic test is a genomics based test discovered using HDC's patented SVM and SVM-RFE pattern recognition technology. This prostate cancer test is based on a unique combination of 4 genes that accurately identify the presence of Grade 3 or higher (clinically significant cancer) prostate cancer cells in prostate tissue. HDC and Clarient will now move to phase two of the clinical trial process to increase the number of specimens tested in order to achieve the statistical significance necessary to validate these very successful initial results. Once the next phase of clinical testing is completed, The Companies will begin the commercialization process. Assuming the data continues to support these initial findings, it is possible that the product could be made available for clinical use by late Q3 of 2008 under the current CLIA regulations. "We are thrilled with the results of this clinical trial and look forward to the commercial launch of this new prostate cancer test with Clarient," stated Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. "The success of this clinical trial also demonstrates that HDC, using our patented SVM and SVM-RFE technology, can develop new molecular diagnostic tests from conception of the idea through clinical discovery and validation of unique genomic signatures that can be commercialized as new molecular diagnostic tests. Our patent protected discovery method allows to us to develop molecular diagnostic tests that are free of outside intellectual property rights and thereby allows HDC to fully patent protect our discovery. We are currently duplicating this process to develop new molecular diagnostic tests in a variety of other cancers." Savannah-based Health Discovery Corporation (OTCBB: HDVY) is uniquely positioned in the field of pattern recognition technology. Through the application of its patent protected technology, HDC is a biology-oriented biomarker discovery company providing all aspects of First-Phase Biomarker Discovery(sm). The Company's SVM and FGM pattern recognition tools have significant application potential in other sizable commercial markets such as radiology, financial markets, Internet search and spam, homeland security, and other areas where analysis of large volumes of complex data is required.Read our full disclaimer at: http://www.realpennies.com/start.html
Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on RealPennies. For more movers: http://www.realpennies.com/wrapup.html
Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice. Sitemap: http://www.realpennies.com/sitemap.html
Sponsored by: http://www.isthemarketopen.com
RealPennies .
Telephone: 1-800-940-6559
Matt /at/ realpennies.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment